MetaVia Inc. (NASDAQ:MTVA) Short Interest Down 67.5% in December

MetaVia Inc. (NASDAQ:MTVA) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 19,683 shares, a drop of 67.5% from the December 15th total of 60,602 shares. Based on an average trading volume of 34,079 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.9% of the shares of the company are sold short. Approximately 0.9% of the shares of the company are sold short. Based on an average trading volume of 34,079 shares, the days-to-cover ratio is currently 0.6 days.

MetaVia Stock Performance

Shares of NASDAQ MTVA traded down $2.33 during midday trading on Wednesday, reaching $5.42. 247,622 shares of the company were exchanged, compared to its average volume of 31,084. The stock’s 50-day moving average price is $8.45 and its 200-day moving average price is $8.74. MetaVia has a one year low of $5.23 and a one year high of $23.87.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($2.86) by $1.32. On average, equities analysts expect that MetaVia will post -3.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. Institutional investors own 1.37% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on MTVA. Wall Street Zen raised shares of MetaVia to a “sell” rating in a research note on Saturday, January 3rd. HC Wainwright upped their price objective on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MetaVia currently has a consensus rating of “Hold” and a consensus target price of $36.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.